BioCentury
ARTICLE | Clinical News

Celgosivir: Expand Phase II

February 4, 2008 8:00 AM UTC

Migenix plans to increase enrollment in order to include a 600 mg celgosivir arm in an ongoing 12-week, Canadian Phase II trial that was evaluating peginterferon alfa-2b and ribavirin with or without ...